作者
Enli Liu,David Marín,Pinaki P. Banerjee,Homer A. Macapinlac,Philip A. Thompson,Rafet Başar,Lucila Nassif Kerbauy,Bethany J Overman,Peter F. Thall,Mecit Kaplan,Vandana Nandivada,Indresh Kaur,Ana Karen Nunez Cortes,Kai Cao,May Daher,Chitra Hosing,Evan N. Cohen,Partow Kebriaei,Rohtesh S. Mehta,Sattva S. Neelapu,Yago Nieto,Michael Wang,William G. Wierda,Michael J. Keating,Richard E. Champlin,Elizabeth J. Shpall,Katayoun Rezvani
摘要
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown remarkable clinical efficacy in B-cell cancers. However, CAR T cells can induce substantial toxic effects, and the manufacture of the cells is complex. Natural killer (NK) cells that have been modified to express an anti-CD19 CAR have the potential to overcome these limitations.
不配.
Singularity
坚强的广山
一一
Leonardi
Yziii
paparazzi221
eternity136
8R60d8
寻道图强
shinysparrow
xiaoming
HEIKU
pluto
好困
tuanheqi
kento
完美的天空
菠菜
sugarxy
皖公网安备34019202002308
